Xiao Ma
Juping Chen2- 1Preventive Care Department, Jinhua Maternity and Child Health Care Hospital, Jinhua, Zhejiang, China
- 2Jinhua Maternity and Child Health Care Hospital, Jinhua, Zhejiang, China
Disseminated Bacille Calmette-Guérin (BCG) disease is a rare adverse reaction to BCG vaccination. We report a neonate presenting with a progressive left axillary mass 3 months post-vaccination. High-throughput sequencing confirmed Mycobacterium bovis (BCG strain) infection. Genetic testing confirmed inborn errors of immunity (IEI) caused by interleukin (IL) 12 receptor β1 deficiency. An expert panel diagnosed BCG disease (acute hematogenous disseminated BCG disease and axillary lymph node involvement) due to the immunodeficiency. After about 28 months of anti-BCG combination therapy with interferon-gamma (IFN-γ), the infection was successfully controlled. The patient continues to receive maintenance therapy with only interferon-gamma (IFN-γ). The study explores the optimal timing and target populations for BCG vaccination in high TB burden countries to minimize severe adverse effects.
1 Introduction
Tuberculosis remains a major global public health threat. In 2023, the World Health Organisation estimated a worldwide tuberculosis incidence of 134 per 100,000 population, ranking it as the first leading cause of death from a single infectious agent (1). Since 1921, the Bacille Calmette–Guérin (BCG) vaccine has been the only available vaccine for tuberculosis prevention (2). Although generally safe, BCG vaccination can lead to adverse events, with an estimated incidence ranging from 100 to 1000 per million doses. Among these, disseminated BCG disease is one of the most severe complications, occurring in approximately 1.56 to 4.29 per million doses, and is associated with high mortality (3). This study presents a representative case of an infant who developed a progressively enlarging left axillary mass three months after BCG vaccination. Genetic testing confirmed inborn errors of immunity (IEI) with interleukin (IL) 12 receptor β1 mutation. We report the first Mendelian susceptibility to mycobacterial disease (MSMD) case caused by a novel IL12RB1 compound heterozygous mutation, c.731C>A (p.S244X) at exon 8. This finding expands the known mutation spectrum of this gene. The diagnosis process of this case commenced with the clinical phenotype of BCG disease and proceeded to explore the underlying immunodeficiency background by genetic testing, thereby achieving precise disease tracing and personalized treatment.
2 Case presentation
The patient was a full-term female infant delivered by spontaneous vaginal delivery, with a birth weight of 3200 g and an Apgar score of 10. Her parents denied any family history of hereditary diseases. According to the standard immunization schedule, she received 0.1 ml of the Bacillus Calmette-Guérin (BCG) vaccine and the first dose of the hepatitis B vaccine within 24 hours after birth. At three months of her age, she was initially seen at a local pediatric outpatient clinic for a “rash for 2 days”. Physical examination revealed polymorphic red maculopapular eruptions on the face and neck without exudation. She was re-evaluated the following day for a “red, swollen mass in the left axilla for 24 hours”. Examination showed an oval-shaped mass in the left axilla with marked tenderness (2+). The affected limb had a normal range of motion, and no systemic symptoms, such as fever, were present. Laboratory tests revealed an elevated C-reactive protein level of 29.78 mg/l and a white blood cell count of 17.67×109/l (neutrophils 43.6%). Other inflammatory markers were within normal limits. Appropriate medical treatment directed at the infection and symptoms was provided. On day 4 of the illness, the patient returned with a low-grade fever (peak temperature 38.1°C). Axillary ultrasound revealed multiple enlarged lymph nodes, with the largest mass in the left axilla measuring approximately 6.0 cm × 4.0 cm. The local skin temperature was elevated, the infant exhibited marked crying upon palpation, and no fluctuation was detected. Due to the poor response to local treatment and progression of systemic inflammatory signs, the patient was hospitalized for further systemic evaluation and intensified therapy. The key clinical information was presented on a timeline (Figure 1).
Figure 1. This figure shows the patient’s timeline of care and highlights the key dates and major interventions.
3 Evaluation
Physical examination upon admission revealed a body temperature of 38.1°C. Laboratory results of blood count were presented in Table 1. On hospital day 3, an abscess incision and drainage procedure was performed. Acid-fast staining of the pus was positive (4+). Metagenomic Next-Generation Sequencing (mNGS) detected Mycobacterium tuberculosis complex infection, and subsequent species identification confirmed Mycobacterium bovis (BCG strain). Fourteen days after symptom onset, the patient was transferred to a tertiary hospital for further management. Examination at that time revealed a 0.5 × 0.5 cm inflammatory induration at the BCG inoculation site. The complete blood count, lymphocyte subset, immunoglobulin, and complement results from the patient’s second admission were shown in Tables 1–3, respectively. Immunological tests for tuberculosis (T-SPOT.TB and PPD skin test) were both negative. To investigate a potential underlying immunodeficiency, trio whole-exome sequencing (WES) was performed. The results identified compound heterozygous mutations in the IL12RB1 gene: a maternally inherited mutation at Exon 8, c.731C>A (p.S244X), and a paternally inherited mutation at Exon 7, c.632 G>C (p.R211P).
Table 1. Hematological findings in the patient’s blood sample.
Table 2. Patient lymphocyte subset flow cytometry results.
Table 3. Patient immunoglobulin and complement results.
4 Treatment
Following a 7-day inpatient course of anti-BCG therapy (rifampicin 75 mg, isoniazid 75 mg, ethambutol 100 mg daily, and linezolid 55 mg three times daily), the patient was discharged upon clinical improvement. She was advised to continue anti-BCG combination therapy with interferon-gamma (IFN-γ) and undergo scheduled follow-up assessments.
5 Outcome and follow-up
A multidisciplinary CDC expert panel concluded that while the underlying IL-12RB1 deficiency was not vaccine-related, the subsequent development of acute hematogenous disseminated BCG disease and axillary lymph node involvement was classified as an adverse reaction to BCG vaccination. The patient attended scheduled follow-ups (monthly until 6 months, then quarterly until 1 year), with additional visits as needed. At her follow-up in Nov. 2024, she was on interferon-gamma (IFN-γ) therapy only, with mild developmental delay but otherwise clinically stable.
6 Discussion
This study describes a novel IL12RB1 mutation and highlights phenotypic variability. Although the paternal mutation in exon 7 (c.632G>C, p.R211P) has been previously reported in a case of recurrent Salmonella enteritidis D sepsis and pneumatocele (4), our patient presented with disseminated BCG disease, demonstrating a distinct clinical phenotype. In contrast, the maternal mutation in exon 8 (c.731C>A, p.S244X) is novel and has not been documented in the literature. As a serious immunization-related adverse event, disseminated BCG disease is often linked to underlying inborn errors of immunity (IEI). IL12RB1 deficiency, a form of Mendelian susceptibility to mycobacterial disease (MSMD), disrupts the IL-12/IFN-γ signaling pathway (5, 6). This impairment affects IL-12 receptor function on NK and T cells, reducing IFN-γ production and compromising Th1 immunity. Consequently, the host loses the ability to clear BCG, leading to systemic dissemination (7).
According to the WHO, China remains a high tuberculosis burden country (1). In accordance with the recommendations of the BCG vaccination position paper, newborns should receive the BCG vaccine as soon as possible (8). To provide early immunization against severe tuberculosis like tuberculous meningitis, it is a national policy in China that all newborns without contraindications receive the BCG vaccine within 24 hours after birth. The BCG vaccine strain used in China is D2PB302, administered via intradermal injection at a dose of 0.1 ml (containing 0.05 mg of Mycobacterium bovis BCG) (9).
Nevertheless, the issue of the optimal timing for BCG vaccination deserves further discussion. IEIs often lack specific clinical manifestations in the neonatal period, making it difficult to identify individuals with underlying immune defects through routine health screening before vaccination. This represents a fundamental limitation in pre-vaccination risk assessment. Considerable variation exists in BCG vaccination policies across countries: in European nations with low tuberculosis incidence, only about 38% implement universal neonatal vaccination; a 2010 survey showed that 35.48% (11/31) of participating countries had completely discontinued routine BCG vaccination for all children (10). Importantly, the decline in BCG vaccination coverage in European and American countries has been accompanied by a concurrent decrease in tuberculosis incidence, suggesting that a targeted vaccination strategy focusing on high-risk populations may be feasible (11). Japan adjusted its vaccination strategy in 2005 by postponing the BCG vaccination age from within 6 months to 5–8 months (no later than 1 year of age), and further revised it in 2013 to vaccination under 1 year of age (12), aiming to allow a longer time window for IEI screening. Subsequent active surveillance data showed that the incidence of disseminated BCG disease was 1.3 per 100,000 doses among those vaccinated before 6 months of age, compared to 0.6 per 100,000 doses among those vaccinated at 6 months or older. Although no statistically significant difference was observed between the two groups—possibly due to the low incidence of disseminated disease and limited sample size—the data still suggest a potential safety advantage associated with delayed vaccination. Following the 2016 policy adjustment in the Taiwan province of China that delayed BCG vaccination from within 5 months to after 5 months of age, the incidence of BCG-induced osteomyelitis decreased from 41.4 to 7.9 cases per million, and no significant increase in tuberculous meningitis was observed, despite a subsequent decline in vaccination coverage to 53% (13, 14).
Appropriately delaying BCG vaccination may help extend the clinical observation window and facilitate early identification of immunodeficiency. However, in high tuberculosis burden areas, newborns still face significant risks from Mycobacterium tuberculosis infection. The WHO explicitly recommends that in regions with high tuberculosis prevalence, newborns should receive the BCG vaccine as soon as possible after birth, as this strategy demonstrates a favorable cost-effectiveness ratio. However, significant disparities in tuberculosis incidence exist among different provinces in mainland China. According to the data (15), the reported incidence of pulmonary tuberculosis in some provinces has fallen below 40 per 100,000 population. In such low-incidence settings, the public health benefits of widespread BCG vaccination may be outweighed by the potential risks. Therefore, a routine BCG vaccination strategy for all newborns immediately after birth may no longer be applicable in regions with lower tuberculosis incidence.
While BCG vaccination is safe for the general population and remains a cornerstone of neonatal immunization in many regions, policy adjustments may be warranted in low-incidence settings. However, in infants with specific IEI, BCG vaccination can lead to severe complications, and BCG disease may even serve as the initial clinical manifestation of underlying immune defects. Studies indicate that among Severe Combined Immunodeficiency (SCID) infants receiving BCG vaccination, approximately 51% develop related complications, with about two-thirds manifesting granulomatous disease and one-third presenting localized disease (16). Although individual IEI with BCG-osis conditions are rare, they are associated with significantly high mortality rates (17). In Singapore, following routine BCG vaccination shortly after birth and synchronous newborn screening for SCID, infants with abnormal results receive immediate anti-mycobacterial therapy (18). Accumulating evidence from multiple countries and regions confirms that routine immunological screening before BCG vaccination represents a necessary and effective public health strategy (19, 20).
In summary, while disseminated BCG disease is a rare complication of vaccination, it carries a grave prognosis, particularly in individuals with undiagnosed IEIs, with mortality rates ranging from 50% to 70% (21). These findings highlight the need to reevaluate clinical practice: in high tuberculosis burden countries, particular attention must be paid to the timing and targeting of BCG immunization. There is an urgent need to develop and implement clinically feasible strategies for early identification of infants at risk of immunodeficiency—such as through family history assessment, newborn screening, or rapid immunologic testing—before vaccine administration. Enhancing clinical vigilance and adopting a more individualized approach to BCG vaccination may significantly reduce the incidence of these severe adverse events and improve overall safety outcomes in national immunization programs.
Data availability statement
The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.
Ethics statement
The studies involving humans were approved by Research and Ethics Committee of Jinhua Maternity and Child Health Care Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants’ legal guardians/next of kin. Written informed consent was obtained from the minor(s)’ legal guardian/next of kin for the publication of any potentially identifiable images or data included in this article. Written informed consent was obtained from the participant/patient(s) for the publication of this case report.
Author contributions
XM: Writing – original draft, Writing – review & editing. JupC: Writing – original draft. JunC: Data curation, Project administration, Writing – original draft. JW: Data curation, Investigation, Writing – original draft.
Funding
The author(s) declared that financial support was not received for this work and/or its publication.
Conflict of interest
The authors declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was used in the creation of this manuscript. Language polishing and translation,grammar checking.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. World Health Organization. Global tuberculosis report 2024. Geneva: World Health Organization (2024).
2. Calmette A. Preventive vaccination against tuberculosis with BCG. Proc R Soc Med. (1931) 24:1481–90. doi: 10.1177/003591573102401109
3. Talbot EA, Perkins MD, Silva SF, and Frothingham R. Disseminated bacille Calmette-Guérin disease after vaccination: case report and review. Clin Infect Dis. (1997) 24:1139–46. doi: 10.1086/513642
4. Lee WI, Huang JL, Lin TY, Hsueh C, Wong AM, Hsieh MY, et al. Chinese patients with defective IL-12/23-interferon-gamma circuit in Taiwan: partial dominant interferon-gamma receptor 1 mutation presenting as cutaneous granuloma and IL-12 receptor beta1 mutation as pneumatocele. J Clin Immunol. (2008) 29:238–45. doi: 10.1007/s10875-008-9253-9
5. Bustamante J, Boisson-Dupuis S, Abel L, and Casanova JL. Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-γ immunity. Semin Immunol. (2014) 26:454–70. doi: 10.1016/j.smim.2014.09.008
6. Khavandegar A, Mahdaviani SA, Zaki-Dizaji M, Khalili-Moghaddam F, Ansari S, Alijani S, et al. Genetic, immunologic, and clinical features of 830 patients with Mendelian susceptibility to mycobacterial diseases (MSMD): A systematic review. J Allergy Clin Immunol. (2024) 153:1432–44. doi: 10.1016/j.jaci.2024.01.021
7. Raghuraman K, S R, Rajkhowa P, and Kaushik JS. Overview of mendelian susceptibility to mycobacterial diseases (MSMD). Cureus. (2025) 17:e85872. doi: 10.7759/cureus.85872
8. World Health Organization. BCG vaccine: WHO position paper, February 2018 - Recommendations. Vaccine. (2018) 36:3408–10. doi: 10.1016/j.vaccine.2018.03.009
9. Li J, Lu J, Wang G, Zhao A, and Xu M. Past, present and future of bacillus calmette-gue rin vaccine use in China. Vaccines (Basel). (2022) 10:1157. doi: 10.3390/vaccines10071157
10. Dierig A, Tebruegge M, Krivec U, Heininger U, and Ritz N. Current status of Bacille Calmette Guérin (BCG) immunisation in Europe - A ptbnet survey and review of current guidelines. Vaccine. (2015) 33:4994–9. doi: 10.1016/j.vaccine.2015.06.097
11. Lancione S, Alvarez JV, Alsdurf H, Pai M, and Zwerling AA. Tracking changes in national BCG vaccination policies and practices using the BCG World Atlas. BMJ Glob Health. (2022) 7:e007462. doi: 10.1136/bmjgh-2021-007462
12. Okuno H, Satoh H, Morino S, Arai S, Ochiai M, Fujita K, et al. Characteristics and incidence of vaccine adverse events after Bacille Calmette-Guérin vaccination: A national surveillance study in Japan from 2013 to 2017. Vaccine. (2022) 40:4922–8. doi: 10.1016/j.vaccine.2022.05.055
13. Lai WC, Yang CH, Huang YC, Chiu NC, and Chen CJ. Spectrum and incidence of adverse reactions post immunization in the Taiwanese population (2014-2019): an analysis using the national vaccine injury compensation program. Vaccines (Basel). (2024) 12:1133. doi: 10.3390/vaccines12101133
14. Chien Y, Yu H, Lee N, Ho H, Kao S, Lu M, et al. Newborn screening for severe combined immunodeficiency in Taiwan. Int J Neonatal Screen. (2017) 3:16. doi: 10.3390/ijns3030016
15. Hu M, Feng Y, Li T, Zhao Y, Wang J, Xu C, et al. Unbalanced risk of pulmonary tuberculosis in China at the subnational scale: spatiotemporal analysis. JMIR Public Health Surveill. (2022) 8:e36242. doi: 10.2196/36242
16. Fekrvand S, Yazdani R, Olbrich P, Gennery A, Rosenzweig SD, Condino-Neto A, et al. Primary immunodeficiency diseases and Bacillus Calmette-Guérin (BCG)-vaccine-derived complications: a systematic review. J Allergy Clin Immunol Pract. (2020) 8:1371–86. doi: 10.1016/j.jaip.2020.01.038
17. Al-Herz W, Husain EH, Adeli M, Al Farsi T, Al-Hammadi S, Al Kuwaiti AA, et al. BCG vaccine-associated complications in a large cohort of children with combined immunodeficiencies affecting cellular and humoral immunity. Pediatr Infect Dis J. (2022) 41:933–7. doi: 10.1097/INF.0000000000003678
18. Chan SB, Zhong Y, Lim SCJ, Poh S, Teh KL, Soh JY, et al. Implementation of universal newborn screening for severe combined immunodeficiency in Singapore while continuing routine Bacille-Calmette-Guerin vaccination given at birth. Front Immunol. (2021) 12:794221. doi: 10.3389/fimmu.2021.794221
19. de Felipe B, Olbrich P, Lucenas JM, Delgado-Pecellin C, Pavon-Delgado A, Marquez J, et al. Prospective neonatal screening for severe T- and B-lymphocyte deficiencies in Seville. Pediatr Allergy Immunol. (2015) 27:70–7. doi: 10.1111/pai.12501
20. Chien YH, Chiang SC, Chang KL, Yu HH, Lee WI, Tsai LP, et al. Incidence of severe combined immunodeficiency through newborn screening in a Chinese population. J Formos Med Assoc. (2015) 114:12–6. doi: 10.1016/j.jfma.2012.10.020
21. Dashti AS, Shahrbabaki SS, Malekzadeh Y, Davarpanah A, Taherifard E, Ahmadkhani A, et al. Characteristics of patients with disseminated bacillus calmette–guérin infection: a retrospective study at namazi hospital, southern Iran, from 1991 to 2022. J Trop Pediatr. (2025) 71:fmae031. doi: 10.1093/tropej/fmaf023
Keywords: Bacille Calmette-Guérin (BCG) vaccine, disseminated BCG disease, IL12RB1 mutation, immunology, mendelian susceptibility to mycobacterial disease
Citation: Ma X, Chen J, Cheng J and Wang J (2026) Case report: IL12RB1 deficiency in an infant with disseminated Bacille Calmette-Guérin disease. Front. Immunol. 16:1728612. doi: 10.3389/fimmu.2025.1728612
Received: 20 October 2025; Accepted: 15 December 2025; Revised: 27 November 2025;
Published: 26 January 2026.
Edited by:
Jacinta Bustamante, Université Paris Cité, FranceReviewed by:
Mahnaz Jamee, Research Institute for Children’s Health (RICH), IranChristine Anterasian, University of Washington, United States
Copyright © 2026 Ma, Chen, Cheng and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xiao Ma, bWF4aWFvMjAxMzEyNDNAbmptdS5lZHUuY24=